media – Page 4 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

The sampling results failed, and the core products of Weiming Pharmaceutical were suspended from purchase in many places

Less than a year after the centralized procurement results were implemented, the human interferon α2b spray produced by Tianjin Weiming Biopharmaceutical Co., Ltd. (hereinafter referred to as “Tianjin Weiming”) was suspended from purchase in some areas. On March 26, the Tibet Autonomous Region Medical Security Bureau (hereinafter referred to as “Tibet Medical Security Bureau”) issued the “Notice on Suspending the Purchase of Human Interferon α2b Spray of Tianjin Weiming Biopharmaceutical Co., Ltd.” The content shows that the drug supervision department recently conducted a random inspection of the α2b spray produced by Tianjin Weiming, and the test results were “biological activity does not meet the regulations.” In accordance with relevant requirements, it is recommended that medical institutions in the region suspend the purchase of human interferon α2b spray produced by Tianjin Weiming, and the selected enterprises are sealed and recalled, and the resumption time will be notified separately. Based on this, ...
- Source: drugdu
- 44
- April 2, 2025
innovation-driven construction of a recovery curve, and new industry layout opens up growth space

Haier Bio (688139.SH) released its 2024 annual performance report. The company achieved a total operating income of 2.284 billion yuan for the whole year, and resumed positive growth. After the growth rate of operating income turned positive year-on-year in the third quarter, the growth rate in the fourth quarter further increased to 10.40%, and the business recovery trend was significant. It is worth noting that in 2024, the company’s new industry performed well, with an annual growth rate of 21.25%, and the proportion of main operating income further increased to 45.47%, an increase of 7.93 percentage points year-on-year. The results of the strategic transformation have been fully verified, and the company’s “second growth curve” has gradually emerged. Data shows that Haier Bio’s ability to rely on technological innovation and AI deep empowerment to continuously iterate digital scene solutions has entered the period of achievement transformation. From the perspective of business ...
- Source: drugdu
- 43
- April 2, 2025
【EXPERT Q&A】What is the difference between siRNA and shRNA in RNA interference technology?

Drugdu.com expert’s response: I. Molecular Structure and Synthesis siRNA: A chemically synthesized or in vitrotranscribed double-stranded RNA molecule, comprising 21–23 base pairs with 2–3 nucleotide overhangs at both ends. Directly delivered to the cytoplasm, where it binds to the RNA-induced silencing complex (RISC) to guide targeted mRNA cleavage. Rapid onset of action (within hours) but has a shorter half-life (typically hours to two days), requiring repeated dosing. Recent advancements in chemical modifications (e.g., 2′-O-methylation, phosphorothioate bonds) have extended stability to ~1 week. Systemic delivery still relies on lipid nanoparticles or GalNAc conjugation for tissue targeting. shRNA: A single-stranded RNA delivered via plasmid or viral vectors. Its hairpin structure is transcribed by RNA polymerase III (Pol III) in the nucleus and processed by Dicer enzyme into functional siRNA. Delayed onset (24–72 hours) but offers sustained gene silencing for weeks to months. Ideal for stable gene knockdown models (e.g., neurodegenerative disease studies using ...
- Source: drugdu
- 46
- April 2, 2025
The first domestic case! Hair transplant surgery robot successfully completed commercial landing

Recently, the first hair transplant robot surgery in China was fully operational at the Run Run Shaw International Medical Center, successfully completing a hair transplant surgery for a 45 year old patient. The success of this surgery has a milestone dual significance: on the one hand, Run Run Shaw International Medical Center’s full process medical care has opened a new era of intelligent and precise hair transplant surgery; On the other hand, as the first domestically produced hair transplant robot to achieve commercialization in China, “Shuzhidao” has successfully broken the foreign technology monopoly and fully demonstrated the innovation strength of Chinese medical technology enterprises. 01. Customized human-machine collaboration solution, reshaping the gold standard of surgery The patient recently sought a hair transplantation solution at the Run Run Shaw International Medical Center. After a series of comprehensive and detailed preoperative examinations and evaluations, Dr. Zhou Qiang, a senior expert in the ...
- Source: drugdu
- 56
- April 1, 2025
Keeler’s first Chinese manufacturing base landed and put into operation

Recently, Keeler, a well-known ophthalmic medical equipment brand under the British company Haomai Group, announced that its first manufacturing base in China has been officially completed and put into operation in Shanghai. This measure marks Keeler’s comprehensive launch of localization strategy, which will further enhance its competitiveness in the Chinese market and inject new vitality into the Chinese ophthalmic medical industry. It is reported that Keeler, as an important member of the medical division of Haomai Group, has been committed to providing high-quality examination and treatment equipment for ophthalmologists worldwide. The establishment of the Chinese manufacturing base is a crucial step for Keeler to expand into the Asian market. 01. The first Chinese manufacturing base has been officially completed According to data, Keeler, a British company founded in 1917, is a globally renowned provider of modern medical examination solutions, with its main business covering over 100 countries. In 1953, Keeler ...
- Source: drugdu
- 62
- April 1, 2025
Olin Biotechnology’s net profit attributable to the parent company in 2024 increased by 18.2% to 20.76 million yuan

On March 30, Olin Biotechnology (688319) announced its 2024 annual report. The company’s operating income was 589 million yuan, up 18.7% year-on-year; net profit attributable to the parent company was 20.76 million yuan, up 18.2% year-on-year; net profit attributable to the parent company after deducting non-recurring items was 11.18 million yuan, up 230% year-on-year; net operating cash flow was -9.73 million yuan, down 122.1% year-on-year; EPS (fully diluted) was 0.0511 yuan. In the fourth quarter, the company’s operating income was 202 million yuan, up 40.6% year-on-year; net profit attributable to the parent company successfully turned losses from a loss of 12.73 million yuan in the same period last year, and realized a net profit attributable to the parent company of 16.73 million yuan; net profit attributable to the parent company after deducting non-recurring items successfully turned losses from a loss of 15.54 million yuan in the same period last year, ...
- Source: drugdu
- 51
- April 1, 2025
Trump’s “withdrawal” seriously affects the operation of the organization, and the WHO will lay off some managers

According to a memorandum recently signed by WHO Director-General Tedros, due to the funding cuts by the Trump administration of the United States, the organization’s overall budget has been cut by more than 1/5, and layoffs will have to be taken. Public health and climate change are among the key issues with the broadest consensus in the world today. Trump ordered his withdrawal from the organization during his first term, citing WHO’s improper handling of the COVID-19 pandemic and other international health crises. But later, after Biden took office, he led the United States back to various organizations and international agreements, including the WHO and the Paris Climate Agreement. After Trump took office for the second time on January 20 this year, he immediately signed an executive order requiring measures to be taken as soon as possible to suspend any funding, support and resources to the WHO. This has caused ...
- Source: drugdu
- 50
- April 1, 2025
core product registration in Indonesia and Egyptian technology transfer project both approved

On March 29, Chengda Bio (688739.SH)’s official website reported that in March 2025, the company’s freeze-dried human rabies vaccine (Vero cells) downstream production process technology transfer project (hereinafter referred to as: Egyptian technology transfer project) was officially approved by the Egyptian Food and Drug Administration (EDA). Chengda Bio’s rabies vaccine can be exported to Egypt in two categories: finished products and semi-finished products; at the same time, the company’s freeze-dried human rabies vaccine (Vero cells) also officially obtained the registration approval and on-site inspection approval for the finished product issued by the Indonesian Food and Drug Administration (BPOM). Access to Indonesia marks that the company has achieved new breakthroughs in the Southeast Asian market after Thailand, the Philippines, Vietnam and other countries, and has penetrated into the core market of ASEAN. Egypt’s technology transfer project approved, overseas localized production enters a new stage Despite the rapid development of the global ...
- Source: drugdu
- 55
- April 1, 2025
Hisun Pharmaceuticals will turn losses into profits in 2024, with a net profit of 601 million yuan

On the evening of March 28, Hisun Pharmaceuticals (600267) announced its 2024 annual report. The report shows that the company achieved operating income of 9.787 billion yuan and a net profit of 601 million yuan in 2024. The company said that the performance was able to turn losses into profits, mainly due to the promotion of preparation products, the growth of pharmaceutical raw material business, the increase in sales profit, and the company’s improvement of management efficiency, optimization of resource allocation and utilization efficiency. At the same time, Hisun Pharmaceuticals actively returns to shareholders, and plans to pay cash dividends of 2.10 yuan (including tax) for every 10 shares in 2024. In addition, in 2024, the company adopted a centralized bidding method to implement a share repurchase amount of 96.4589 million yuan, and the cash dividend and repurchase amount totaled 342 million yuan, accounting for 56.87% of the net profit ...
- Source: drugdu
- 52
- April 1, 2025
China Chongqing International Pharmaceutical Machinery Expo Spring (CIPM)

Organiser: China Pharmaceutical Equipment Industry Association Time: April 23-25, 2025 Address: No. 66 Yuelai Avenue, Yubei District, Chongqing Exhibition hall: Chongqing International Expo Center Product range: API Equipment & Machinery: Reaction equipment, tower equipment, crystallization equipment, separation machinery, extraction equipment, heat exchangers, evaporation equipment, distillation equipment, drying machinery, storage equipment, sterilization equipment. Formulation Machinery: Granule machinery, tablet press machines, capsule filling machines, powder injectable machinery, small/large-volume injectable equipment, pill machinery, suppository machinery, ointment machinery, oral liquid machinery, aerosol machinery, ophthalmic preparation machinery, film-coating machinery. Pharmaceutical Packaging Machinery & Materials: Direct packaging machinery, outer packaging machinery, pharmaceutical packaging material manufacturing equipment, packaging materials, packaging production lines, packaging software, integrated packaging solutions. Pharmaceutical Water/Gas Equipment: Process gas/steam equipment, purified water systems, water-for-injection systems, ion exchange equipment. Pharmaceutical Crushing Equipment: Mechanical crushers, jet mills, grinding mills, cryogenic crushers. Traditional Chinese Medicine Processing Machinery: Cleaning machinery, cutting machinery, roasting/frying machinery, drying equipment. Drug Testing Equipment: Hardness testers, ...
- Source: drugdu
- 70
- April 1, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.